Cabaletta Bio, Inc.
NASDAQ:CABABiotechnology
Healthcare
$1.02 +1.23%
+$0.04 today
- Market cap
- $220.03M
- Beta
- 3.23
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.57
52W Low $1.26High $4.23
Volume 5.46M
Average 3.33M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$172.24M
FY 2025 · Annual
Net Income
-$167.86M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 32.49M | 39.3M | 55.42M | 97.2M | 142.67M |
| Selling, General & Admin | 13.82M | 14.84M | 19.24M | 27.94M | 29.57M |
| Operating Expenses | 46.31M | 54.14M | 74.66M | 125.14M | 172.24M |
| Depreciation & Amortization | 733K | 1.18M | 1.43M | 1.71M | 1.65M |
| EBITDA | (45.56M) | (51.8M) | (66.25M) | (113.41M) | (164.21M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (46.31M) | (54.14M) | (74.66M) | (125.14M) | (172.24M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 24K | 1.16M | 6.99M | 10.03M | 6.03M |
| Interest Expense | 0 | 0 | 0 | 748K | 2M |
| Other Income / Expenses | 24K | 1.16M | 6.99M | 9.28M | 4.39M |
| Income Before Tax | (46.29M) | (52.98M) | (67.68M) | (115.86M) | (167.86M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (46.29M) | (52.98M) | (67.68M) | (115.86M) | (167.86M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.80) | (1.81) | (1.65) | (2.34) | (1.64) |
| EPS (Diluted) | (1.80) | (1.81) | (1.65) | (2.34) | (1.64) |
| 25.74M | 29.34M | 40.95M | 49.52M | 102.26M | |
| 25.74M | 29.34M | 40.95M | 49.47M | 102.26M |
CABA Earnings Waterfall · TTM
NASDAQ:CABA · Revenue to Net Income
Key Ratios
EPS$-1.97
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-1.2
P/S Ratio0.0
Analysis
$0 of revenue converted into -$175.4M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.97, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 12, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| 8-K | Current report | Nov 5, 2026 |
How much revenue does CABA generate?
Cabaletta Bio, Inc. (CABA) reported $0.00 of revenue in fiscal 2025.
Is CABA profitable?
Cabaletta Bio, Inc. (CABA) reported -$167.86M of net income.
Continue the stock analysis
Jump to another research area for this company.